WO2013106766A3 - THERAPEUTIC INDICATIONS OF miR-1291 - Google Patents

THERAPEUTIC INDICATIONS OF miR-1291 Download PDF

Info

Publication number
WO2013106766A3
WO2013106766A3 PCT/US2013/021307 US2013021307W WO2013106766A3 WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3 US 2013021307 W US2013021307 W US 2013021307W WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
methods
therapeutic indications
conditions
human diseases
Prior art date
Application number
PCT/US2013/021307
Other languages
French (fr)
Other versions
WO2013106766A2 (en
Inventor
Aiming Yu
Yuzhuo PAN
Jingxin Qiu
Original Assignee
The Research Foundation Of State University Of New York
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of State University Of New York, Health Research, Inc. filed Critical The Research Foundation Of State University Of New York
Publication of WO2013106766A2 publication Critical patent/WO2013106766A2/en
Publication of WO2013106766A3 publication Critical patent/WO2013106766A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Abstract

Provided herein are compositions and methods for preventing and treating human diseases and/or conditions. The present invention relates to, inter alia, the reconstitution of miR-1291 levels in samples and subjects. Also provided herein are methods for the diagnosis and treatment of human diseases and conditions by assessing miR-1291 expression levels. Methods of treating human cancers by modifying or regulating miRNA pathways are also provided.
PCT/US2013/021307 2012-01-13 2013-01-11 THERAPEUTIC INDICATIONS OF miR-1291 WO2013106766A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586446P 2012-01-13 2012-01-13
US61/586,446 2012-01-13

Publications (2)

Publication Number Publication Date
WO2013106766A2 WO2013106766A2 (en) 2013-07-18
WO2013106766A3 true WO2013106766A3 (en) 2013-09-12

Family

ID=48782096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/021307 WO2013106766A2 (en) 2012-01-13 2013-01-11 THERAPEUTIC INDICATIONS OF miR-1291

Country Status (1)

Country Link
WO (1) WO2013106766A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10619156B2 (en) 2014-05-28 2020-04-14 The Regents Of The University Of California Hybrid tRNA/pre-miRNA molecules and methods of use
WO2016153880A2 (en) 2015-03-23 2016-09-29 The Regents Of The University Of California Methods for detection of rnase activity
CN105106959B (en) * 2015-08-16 2018-07-17 深圳市倍昂生物科技有限公司 Application and a kind of pharmaceutical composition of the cordycepin in the drug of preparation and radiotherapy and/or chemotherapy synergistic treatment tumour
CN110088278B (en) * 2016-10-31 2023-08-11 e-NA生物科技公司 Double-stranded nucleic acid molecules and uses thereof
WO2020175898A1 (en) * 2019-02-26 2020-09-03 서울대학교 산학협력단 Pharmaceutical composition for preventing or treating cancer, comprising tut4/7 expression modulator

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (en) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules
WO2010139810A1 (en) * 2009-06-05 2010-12-09 Febit Holding Gmbh Mirna fingerprint in the diagnosis of lung cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (en) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules
WO2010139810A1 (en) * 2009-06-05 2010-12-09 Febit Holding Gmbh Mirna fingerprint in the diagnosis of lung cancer

Also Published As

Publication number Publication date
WO2013106766A2 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
HK1214168A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
MX2022004300A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
MX2019006379A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy.
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EP2294184A4 (en) Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2020011415A (en) Methods of using zscan4 for rejuvenating human cells.
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2018001831A (en) Biomarkers for treatment of alopecia areata.
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2015006096A (en) Leukocytes as delivery cells for imaging and disease therapy.
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
WO2012129395A3 (en) Diagnosis and treatment of prostate cancer
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
MX358072B (en) Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2